Informations générales (source: ClinicalTrials.gov)
Comparison of the Impact on Digestive Portage of Broad Spectrum Beta-Lactamase-Producing Enterobacteriaceae (E-ESBLs) of Proposed Treatments in Outbreaks of Childhood Urinary Tract Infection (MIKA)
Observational
Centre Hospitalier Intercommunal Creteil (Voir sur ClinicalTrials)
janvier 2019
janvier 2025
29 juin 2024
The emergence of extended-spectrum beta-lactamase-producing Enterobacteriaceae (E-ESBL)
is a major public health problem. It leads more frequent prescription of penems with the
risk of emergence and spread of strains producing carbapenemases, which may be resistant
to all known antibiotics. A policy of savings of penems is desirable. Among the
alternatives to penems, amikacin is in the foreground. It remains active on the majority
of E-ESBL strains. Some risk factors for E-ESBL emergence are known: recent antibiotic
therapy (particularly quinolones and cephalosporins third generation), previous
hospitalization or residence in a high endemic country.
In pediatrics, E-ESBLs are primarily responsible for urinary tract infection. In France,
E-ESBLs represent about 10% of the strains responsible for urinary tract infections. The
Pathology Group Pediatric Infectious (GPIP) of the French Society of Pediatrics (SFP) and
the Society of Infectious Pathology French Language (SPILF) have proposed different
therapeutic options to treat febrile UTIs in children: amikacin intravenous; intravenous
(IV) ceftriaxone or intramuscular (IM); or cefixime per-os (PO).
The objective of this study is to compare the emergence of E-ESBLs in stools of children
after febrile UTIs treatment with amikacin IV versus ceftriaxone or cefixime.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHI DE CRETEIL | Emilie GEORGET | 13/05/2024 11:59:14 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| AP-HP - Hôpital Jean Verdier | Aurélien Galerne | Contact (sur clinicalTrials) | |||
| CH DE VERSAILLES SITE ANDRE MIGNOT | Marie-Aliette Dommergues | Contact (sur clinicalTrials) | |||
| CLINIQUE DU DR BOYER | Lucette Coicadan | Contact (sur clinicalTrials) | |||
| IFAC - AP COMBS LA VILLE | François Corrard | Contact (sur clinicalTrials) | |||
| MAISON DE SANTE NOGENT SUR MARNE | Patrice Deberdt | Contact (sur clinicalTrials) | |||
| MSP DU SQUARE CALMETTE | Catherine Turberg-Romain | Contact (sur clinicalTrials) | |||
| MSP SAINT MAUR DES FOSSES | Robert Cohen | Contact (sur clinicalTrials) | |||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Antoine Beclère Hospital - Clamart - Ile-de France - France | Vincent Gadjos | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| 13 Villa Beauséjour - 94300 - Vincennes - France | Christophe BATARD | Contact (sur clinicalTrials) | |||
| 157 Avenue du Général Leclerc - 94700 - Maisons-Alfort - France | Annie ELBEZ | Contact (sur clinicalTrials) | |||
| Cabinet du Dr Benali - 94220 - Charenton-le-Pont - France | Hadj Benali | Contact (sur clinicalTrials) | |||
| Cabinet du Dr Romain - 75015 - Paris - France | Olivier Romain | Contact (sur clinicalTrials) | |||
| Cabinet du Dr Thollot - 54270 - Essey-lès-Nancy - France | Franck Thollot | Contact (sur clinicalTrials) | |||
| Cabinet du Dr Werner - 30400 - Villeneuve-lès-Avignon - France | Andreas Werner | Contact (sur clinicalTrials) | |||
| Cabinet du Dr Wollner - 94130 - Nogent-sur-Marne - France | Alain Wollner | Contact (sur clinicalTrials) | |||
| Centre Hospitalier de Meaux - Meaux - France | Olivier Vignaud | Contact (sur clinicalTrials) | |||
| CHI Villeneuve-Saint-Georges - 94195 - Villeneuve-Saint-Georges - France | Aurélie GARRAFFO | Contact (sur clinicalTrials) | |||
| CHU Le Kremlin-Bicêtre - Le Kremlin-Bicêtre - France | Irina Craiu | Contact (sur clinicalTrials) | |||
| Hospital Robert-Debré - Paris - France | Alexis Rybak | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Infant and child (age ≥ 3 months and <3 years)
- Patient treated for febrile urinary tract infection as monotherapy with amikacin IV,
ceftriaxone (IV or IM) or cefixime PO *
- Whose parents read and understood the newsletter and whose express consent was
collected
- Patient affiliated to a social security scheme (Social Security or Universal Medical
Coverage)
- Infant and child (age ≥ 3 months and <3 years)
- Patient treated for febrile urinary tract infection as monotherapy with amikacin IV,
ceftriaxone (IV or IM) or cefixime PO *
- Whose parents read and understood the newsletter and whose express consent was
collected
- Patient affiliated to a social security scheme (Social Security or Universal Medical
Coverage)
- Child treated with more than one antibiotic (eg treatment with dual therapy
ceftriaxone / cefotaxime and aminoglycoside)
- Antibiotherapy in progress or discontinued in the previous 7 days
- Hospitalized child
- Refusal of one of the parents